MCAT and hepatocellular carcinoma: An oral nanoparticle platform combining sorafenib and salinomycin enhances ferroptosis and immune response in hepatocellular carcinoma, improving therapeutic efficacy by targeting HCC cells through MCT-1-mediated delivery.